Royalty Pharma PLC - Class A (RPRX) closed at $63.86 on October 23, 2026, up 0.2% from the previous close, on volume of 3,536,810 shares (30-day average 2,919,050).
Data as of October 23, 2026.
23-Oct-2026
Royalty Pharma declares fourth quarter 2026 dividend
Globe Newswire (Fri, 16-Oct 8:00 AM ET)
Royalty Pharma to announce third quarter 2026 financial results on November 4, 2026
Globe Newswire (Fri, 9-Oct 8:50 AM ET)
Globe Newswire (Tue, 15-Sep 4:35 PM ET)
Royalty Pharma to present at upcoming investor conferences
Globe Newswire (Wed, 9-Sep 4:05 PM ET)
Royalty Pharma announces update on Novartis' Phase 3 topline results for pelacarsen
Globe Newswire (Fri, 4-Sep 7:05 PM ET)
Royalty Pharma and Zealand Pharma enter into rusfertide funding agreement for $100 million
Globe Newswire (Wed, 12-Aug 4:10 PM ET)
Globe Newswire (Wed, 12-Aug 4:05 PM ET)
Royalty Pharma Raises 2026 Guidance After Double-Digit Growth Across Key Royalty Streams
Market Chameleon (Wed, 5-Aug 5:48 AM ET)
Royalty Pharma reports second quarter 2026 results
Globe Newswire (Wed, 5-Aug 7:00 AM ET)
Royalty Pharma appoints Greg Raskin as Senior Vice President, Head of Academic Initiatives
Globe Newswire (Mon, 3-Aug 8:15 AM ET)
Royalty Pharma PLC is the largest buyer of biopharmaceutical royalties. The firm has a portfolio of royalties that entitles it to payments based on the sales of biopharma products. Royalty Pharma receives royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson's Imbruvica (for chronic lymphocytic leukemia and other blood cancers), Biogen's Tysabri (for relapsing forms of multiple sclerosis), Vertex's cystic fibrosis franchise, and 10 development-stage product candidates.
Royalty Pharma PLC - Class A trades on the NASDAQ stock market under the symbol RPRX.
As of October 23, 2026, RPRX stock price climbed to $63.86 with 3,536,810 million shares trading.
RPRX has a beta of 0.03, meaning it tends to be less sensitive to market movements. RPRX has a correlation of 0.00 to the broad based SPY ETF.
RPRX has a market cap of $28.44 billion. This is considered a Large Cap stock.
Last quarter Royalty Pharma PLC - Class A reported $674 million in Revenue and $1.32 earnings per share. This fell short of revenue expectation by $-121 million and exceeded earnings estimates by $.05.
In the last 3 years, RPRX traded as high as $64.38 and as low as $24.05.
The top ETF exchange traded funds that RPRX belongs to (by Net Assets): VXF, VFLO, IWR, VYM, CGDG.
RPRX has outperformed the market in the last year with a price return of +75.8% while the SPY ETF gained +14.3%. RPRX has also outperformed the stock market ETF in the last 3 month and 2 week periods returning +8.6% and +12.2%, respectively, while the SPY returned +3.2% and -2.4%, respectively.
RPRX support price is $62.77 and resistance is $64.74 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that RPRX shares will trade within this expected range on the day.
